Figure 5 : Control TrkC ligand (IYIY-TEG) has similar immunomodulatory activities as IYIY-I2-BODIPY.

From: Tropomyosin Receptor Kinase C Targeted Delivery of a Peptidomimetic Ligand-Photosensitizer Conjugate Induces Antitumor Immune Responses Following Photodynamic Therapy

Figure 5

4T1 tumor bearing mice were administrated with IYIY-TEG via tail vein (equivalent dose to IYIY-I2-BODIPY) and mice were sacrificed at 2 h and 24 h post administration. Lymphoid organs were harvested and populations of (a) G-MDSCs and Treg cells (b) Th1 (CD4+ IFN-γ+), Th17 (CD4+ IL-17+) and (c) CTLs (CD8+ IFN-γ+), Tc17 (CD8+ IL-17+) cells were quantified using flow cytometry after labeling with fluorescence conjugated antibodies. Data represent mean ± SEM with minimum of four mice per group. *p < 0.05 vs saline control using student’s t-test.